AVIRON
Form 425
January 10, 2002

Pursuant to Rule 4

MedImmune Acquires Aviron Shares in Exchange Offer

Gaithersburg, MD, January 10, 2002 -- MedImmune, Inc. (Nasdaq: MEDI) announced today that it has
(Nasdaq: AVIR) shares which were validly tendered in its offer to exchange 1.075 MedImmune shares

The exchange offer expired at 12:00 midnight, New York City time on January 9, 2002. Approximate
tendered (including 4,248,928 shares tendered pursuant to notice of guaranteed delivery), which c
percent of the total number of outstanding Aviron shares.

MedImmune intends promptly to merge a subsidiary into Aviron, as a result of which Aviron will be
MedImmune. In the merger, each remaining Aviron share will be converted into the right to receiv

The Information Agent for the offer is MacKenzie Partners, Inc., 156 Fifth Avenue, New York, New
212-929-5500 or toll-free at 800-322-2885. The Dealer Manager for the offer is Merrill Lynch & Co
New York, New York 10080. Call collect at 609-274-3066.

Aviron is a biopharmaceutical company headquartered in Mountain View, California, focused on prev
innovative vaccine technologies. The company's product portfolio includes: FluMist , a live virus
mist for the prevention of influenza; a live parainfluenza virus type 3 vaccine; a vaccine to pre
cytomegalovirus vaccine. For more information on Aviron, visit the company's website at www.aviro

MedImmune, Inc. is a fully integrated biotechnology company focused on developing and marketing p
in areas such as infectious disease, immune regulation and cancer. Headquartered in Gaithersburg,
manufacturing facilities in Frederick, Maryland and Nijmegen, the Netherlands. MedImmune markets
Synagis® (palivizumab), which is marketed for the prevention of serious lower respiratory tract d
syncytial virus in pediatric patients at high risk of RSV disease, which is prominent in the Nort
through May (see full prescribing information at www.medimmune.com); Ethyol®, which is marketed f
cumulative renal toxicity associated with repeated administration of cisplatin in patients with a
cell lung cancer and moderate to severe xerostomia in patients undergoing post-operative radiatio
cancer, where the radiation port includes a substantial portion of the parotid (see full prescrib
www.medimmune.com); and CytoGam®, which is marketed for the prophylaxis against cytomegalovirus d
transplantation of kidney, lung, liver, pancreas, and heart (see full prescribing information at
has six products in various stages of clinical testing for a number of diseases and several more
testing. For more information on MedImmune, visit the company's website at www.medimmune.com.

This announcement may contain, in addition to historical information, certain forward-looking sta
uncertainties. Such statements reflect management's current views and are based on certain assump
materially from those currently anticipated as a result of a number of factors, including risks a
MedImmune's and Aviron's filings with the SEC. MedImmune and Aviron are developing products for p
can be no assurance that such development efforts will succeed, that such products will receive r
that, even if such regulatory clearance were received, such products would ultimately achieve com
assurance that Aviron will be integrated successfully or without unanticipated costs.

Aviron stockholders and other investors are urged to read the registration statement on Form S-4,
other exchange offer documents which have been filed or will be filed by MedImmune with the Secur
the related solicitation/recommendation statement filed by Aviron with the SEC. These documents c
should be read carefully before any decision is made with respect to the offer. Documents filed w
at the SEC's website at www.sec.gov. Documents are also available for free from MacKenzie Partner